We are interested in hearing your proposals for collaborating with the PCC
The Precision Cancer Consortium (PCC) aims to make precision oncology and comprehensive genomic testing the new normal. The mission of the PCC is to foster collaboration to improve global patient access to comprehensive genomic testing in routine care and clinical trials.
If you would like to contribute to this important mission through a collaborative project with the PCC, please read the information below and then complete the collaboration proposal form.
The PCC harnesses the power of seven global pharma companies to drive global access to comprehensive genomic testing for all patients with cancer. Challenges that are ecosystem-related cannot be solved by one stakeholder of the healthcare system alone.
The PCC facilitates collaboration of pharma/biotech companies to address challenges regarding access, awareness, as well as research and development of comprehensive genomic testing for cancer patients globally. Find out more about our strategic objectives here.
We are always interested to hear from prospective collaborators who share our vision to make precision oncology and comprehensive genomic testing the new normal. If you would like to contribute to this important mission, please complete the proposal submission form below.
The PCC is currently focussed on improving global patient access to comprehensive genomic testing in routine care and clinical trials through:
- Education and awareness to mitigate barriers to access and increase educational awareness on the value of genomic testing for different stakeholders of the healthcare system
- Research and development to improve efficiencies in genomic testing in clinical trials.
For further information on our current activities click here.
We are interested in collaborative project proposals that will be conducted in partnership with the PCC. Proposals that do not include a significant element of collaboration with the PCC members (e.g., requests for funding only) will not be considered at this time.
The PCC are open to collaborate with healthcare professionals or organisations that share our vision to make precision oncology and comprehensive genomic testing the new normal.
Please be aware that we do not endorse specific companies, technologies, biomarkers or therapeutics. Our goal is to increase patient access to comprehensive genomic testing in routine clinical care and research and development, agnostic of these factors.
We are always interested to hear from prospective collaborators who share our vision to make precision oncology and comprehensive genomic testing the new normal.
Your proposal will be considered in an initial review conducted on a quarterly basis. We may contact you in the intervening period if we require further information.
Once the initial review is complete, we will inform you of the decision. If your proposal passes initial review, you will be invited to present a more detailed submission. Further details will follow accordingly.
